AI Article Synopsis
- Acute pancreatitis (AP) is an inflammatory condition with various causes, including drugs, which account for a small percentage of cases; diagnosing drug-induced AP is often complicated due to a lack of specific symptoms.
- A study conducted at Hospital Universitari de Bellvitge analyzed 38 patients with suspected drug-induced AP from June 2007 to March 2023, revealing that most cases were linked to a single drug, with azathioprine and atorvastatin being the most common culprits.
- The findings suggest that increased awareness and a proposed diagnostic algorithm may improve the identification and management of drug-induced pancreatitis, highlighting the need for drug assessment when diagnosing AP.
Article Abstract
Introduction: Acute pancreatitis (AP) is an inflammatory disease with multiple etiologies, and the emergence of complications. Between 0.1-5% of cases are attributed to drugs. The absence of specific characteristics complicates the diagnosis and treatment of drug-induced AP. Reviewing patients admitted with the diagnosis of drug-induced AP can provide information and improve its management.
Patients And Methods: This is a descriptive, observational, and retrospective study. All patients admitted to the Hospital Universitari de Bellvitge between June 2007 and March 2023 with suspected drug-induced AP were included. The data were obtained from the hospital pharmacovigilance program database.
Results: Thirty-eight patients with suspected drug-induced AP were identified, representing 0.62% of all adverse drug reactions (n=6.085). Of these, 65.8% (n=25) had a single suspected drug. The median latency period for the onset of adverse drug reactions was 160.5 days (IQR: 18-582 days), and the median hospital stay was 5 days (IQR: 3-7 days). Fifty-nine suspected drugs were identified, involving 26 active principles. Azathioprine and atorvastatin were the most frequent, with 9 cases each (15.2%), followed by enalapril with 8 cases (13.6%). Drug etiology was assessed in 23 cases (60.5%), and the suspected drug was discontinued in all cases. There was one fatal case documented (2.63%).
Conclusion: This study can contribute to better understanding of drug-induced pancreatitis episodes. We propose a diagnostic algorithm that includes the assessment of the drug as a possible cause.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medcli.2024.07.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of the serotonin release assay with enterochromaffin cell-rich human intestinal organoids for the risk evaluation of drug-induced emesis.
Toxicol Sci
December 2024
Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
Drug-induced emesis is one of the major symptoms of gastrointestinal toxicity. Preclinical risk assessment of emesis has been challenging owing to the lack of suitable animal models or in vitro assay systems. One of the triggers of emesis is an excessive serotonin (5-HT) release from enterochromaffin (EC) cells in the intestinal tract, which activates the vomiting center in the brain stem and elicits the vomiting reflex.
View Article and Find Full Text PDFHepatitis and Hepatitis B Virus Reactivation in Everolimus-Treated Solid Tumor Patients: A Focus on HBV-Endemic Areas.
Cancers (Basel)
November 2024
School of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Article Synopsis
- Everolimus, a drug for treating certain cancers, poses a risk of hepatitis B virus (HBV) reactivation and hepatitis, particularly in patients with current or past HBV infection.
- A study involving 377 patients on everolimus found that 28.75% of those with active HBV (HBsAg-positive) and 17.85% of those without (HBsAg-negative) developed hepatitis, with higher risks associated with specific treatments and lack of prophylaxis.
- The research emphasizes the need for HBV screening and careful liver function monitoring for patients receiving everolimus, especially in regions where HBV is common.
Control compounds for drug-induced liver injury evaluation: Evidence from Database of Adverse Event Notifications.
J Hepatol
December 2024
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Jiangsu, China; Subei People's Hospital, Jiangsu, China. Electronic address:
Midostaurin-Associated acute pancreatitis.
J Oncol Pharm Pract
December 2024
Department of Internal Medicine, University of Health Sciences - Adana Health Practice and Research Center, Adana, Turkey.
Article Synopsis
- Midostaurin is the first targeted treatment for AML FLT3 and reduces mortality by 23% compared to standard chemotherapy, but it has side effects, especially gastrointestinal issues.
- A case was reported where a patient experienced acute pancreatitis symptoms after starting midostaurin, including abdominal pain and elevated enzyme levels.
- The patient was treated with IV hydration and anti-symptomatic care, recovering after four days, but drug-induced acute pancreatitis remains a rare and complicated diagnosis without established links to midostaurin despite various potential mechanisms.
Rectal 5-aminosalicylic acid induced pancreatitis in a patient with newly diagnosed ulcerative colitis.
Clin J Gastroenterol
November 2024
Department of Gastroenterology, University Hospital Geelong, Barwon Health, 272 Ryrie Street Geelong, Geelong, Victoria, 3220, Australia.
Oral 5-aminosalicylic acid (5-ASA) are well recognised to have the potential to cause drug-induced acute pancreatitis; however, there have only been infrequent case reports of rectal formulations causing acute pancreatitis. We describe a case of rectal Mesalazine (a 5-ASA) induced acute pancreatitis. The patient was commenced on rectal 5-ASA therapy 8 weeks prior to presentation following a diagnosis of Montreal classification E1 Ulcerative Colitis on colonoscopy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!